Compare
Scienture Holdings, Inc. vs Medicinova Inc vs Mereo BioPharma Group plc vs Lipella Pharmaceuticals Inc.
| Latest fiscal year | Scienture Holdings, Inc. SCNX | Medicinova Inc MNOV | Mereo BioPharma Group plc MREO | Lipella Pharmaceuticals Inc. LIPOLast annual report: year ended 2024-12-31 |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2024-12-31 |
| Revenue | $431.6K | $409.7K | $500.0K | $536.4K |
| Revenue growth (YoY) | +215.9% | n/a | n/a | +19.3% |
| Gross margin | 76.8% | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | -947.2% |
| Net margin | n/m | n/m | n/m | -935.2% |
| Net income | -$41.51M | -$12.00M | -$41.88M | -$5.02M |
| EPS (Diluted) | -$2.70 | -$0.24 | -$0.05 | -$4.79 |
| Operating cash flow | -$13.38M | -$9.81M | -$30.97M | -$3.95M |
| Free cash flow | n/a | -$9.81M | -$30.99M | n/a |
| Cash & equivalents | $6.66M | $30.81M | $40.99M | $2.18M |
| Total assets | $84.18M | $45.60M | $45.92M | $2.67M |
| Total liabilities | $14.06M | $4.02M | $5.00M | $754.4K |
| Shareholders' equity | $70.12M | $41.59M | $40.92M | $1.92M |
| Return on year-end equity | -59.2% | -28.9% | -102.4% | -261.3% |
| Shares outstanding | 40.63M | 49.22M | n/a | 1.21M |
Revenue, most recent five fiscal years
| Fiscal year | Scienture Holdings, Inc. | Medicinova Inc | Mereo BioPharma Group plc | Lipella Pharmaceuticals Inc. |
|---|---|---|---|---|
| Latest | $431.6K Ended 2025-12-31 | $409.7K Ended 2025-12-31 | $500.0K Ended 2025-12-31 | $536.4K Ended 2024-12-31 |
| 1 year earlier | $136.6K Ended 2024-12-31 | n/a | $0 Ended 2024-12-31 | $449.6K Ended 2023-12-31 |
| 2 years earlier | $1.36M Ended 2023-12-31 | $1.00M Ended 2023-12-31 | $10.00M Ended 2023-12-31 | $184.2K Ended 2022-12-31 |
| 3 years earlier | $10.25M Ended 2022-12-31 | n/a | $0 Ended 2022-12-31 | $259.3K Ended 2021-12-31 |
| 4 years earlier | $9.89M Ended 2021-12-31 | $4.04M Ended 2021-12-31 | n/a | n/a |